Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

• Published in: Haematologica (Roma) Vol. 92; no. 11; pp. 1579 - 1580
• Main Authors: Palandri, Francesca, Iacobucci, Ilaria, Quarantelli, Fabrizio, Castagnetti, Fausto, Cilloni, Daniela, Baccarani, Michele, on behalf of GIMEMA Working Party on CML
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.11.2007
• Subjects: Benzamides; Cytogenetics; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase - diagnosis; Leukemia, Myeloid, Chronic-Phase - drug therapy; Piperazines - administration & dosage; Pyrimidines - administration & dosage; Time Factors
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.12033

* Department of Hematology/Oncology "L. and A. Seràgnoli" S. Orsola-Malpighi Hospital, University of Bologna, Bologna; ° CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples; # Department of Clinical and Biological Science, University of Turin at Orbassano, Turin, Italy Correspondence: Francesca Palandri, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", St. Orsola-Malpighi University Hospital, via Massarenti, 9, 40138 Bologna, Italy. Phone: international +39.051.6363680. Fax: international +39. 051.6364037. E-mail: francesca.palandri{at}libero.it CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response (MolR) of 54 early chronic phase (ECP) and of 115 late CP patients who achieved a stable CCgR with IM 400 mg/daily. ECP patients obtained earlier, higher and more sustained MMolR.